Faricimab治疗先前接受抗vegf治疗的糖尿病黄斑水肿患者的早期结果

IF 0.9 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2025-04-18 DOI:10.3928/23258160-20250228-01

Nitesh Mohan, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma

{"title":"Faricimab治疗先前接受抗vegf治疗的糖尿病黄斑水肿患者的早期结果","authors":"Nitesh Mohan, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma","doi":"10.3928/23258160-20250228-01","DOIUrl":null,"url":null,"abstract":"Background and objective: The aim of this study was to evaluate the short-term outcomes of switching to intravitreal faricimab injections (IFIs) from prior anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of diabetic macular edema (DME).Patients and methods: A retrospective review was done of patients with DME previously treated with anti-VEGF and subsequently switched to IFIs. Optical coherence tomography scans were assessed qualitatively and quantitatively to evaluate intraretinal fluid changes and central subfield thickness (CST).Results: A total of 62 eyes from 41 patients were analyzed with a mean follow-up time of 36.4 ± 14.4 weeks. After receiving three IFIs, treatment interval increased significantly by 3.2 weeks (P < 0.001), CST decreased significantly by 43.8 µm (P = 0.014), and visual acuity remained stable (63.2 vs 64.4 approximate ETDRS letters, P = 0.720). Seventeen eyes (27.4%) were switched back to their prior anti-VEGF agent, with one case of suspected IFI-related uveitis.Conclusion: Faricimab appears to be a viable option for some DME patients who require a change in anti-VEGF therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"1-7"},"PeriodicalIF":0.9000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early Outcomes of Faricimab Treatment for Diabetic Macular Edema in Patients Previously Treated With Anti-VEGF Therapy.\",\"authors\":\"Nitesh Mohan, Andrei Szigiato, Katherine E Talcott, Danny A Mammo, Amy S Babiuch, Peter K Kaiser, Justis P Ehlers, Aleksandra Rachitskaya, Alex Yuan, Sunil K Srivastava, Sumit Sharma\",\"doi\":\"10.3928/23258160-20250228-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objective: The aim of this study was to evaluate the short-term outcomes of switching to intravitreal faricimab injections (IFIs) from prior anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of diabetic macular edema (DME).Patients and methods: A retrospective review was done of patients with DME previously treated with anti-VEGF and subsequently switched to IFIs. Optical coherence tomography scans were assessed qualitatively and quantitatively to evaluate intraretinal fluid changes and central subfield thickness (CST).Results: A total of 62 eyes from 41 patients were analyzed with a mean follow-up time of 36.4 ± 14.4 weeks. After receiving three IFIs, treatment interval increased significantly by 3.2 weeks (P < 0.001), CST decreased significantly by 43.8 µm (P = 0.014), and visual acuity remained stable (63.2 vs 64.4 approximate ETDRS letters, P = 0.720). Seventeen eyes (27.4%) were switched back to their prior anti-VEGF agent, with one case of suspected IFI-related uveitis.Conclusion: Faricimab appears to be a viable option for some DME patients who require a change in anti-VEGF therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].\",\"PeriodicalId\":19679,\"journal\":{\"name\":\"Ophthalmic surgery, lasers & imaging retina\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic surgery, lasers & imaging retina\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/23258160-20250228-01\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20250228-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的：本研究的目的是评估从先前的抗血管内皮生长因子（抗vegf）治疗转向玻璃体内法利西单抗注射（IFIs）治疗糖尿病性黄斑水肿（DME）的短期结果。患者和方法：对先前接受抗vegf治疗并随后改用IFIs治疗的DME患者进行了回顾性研究。对光学相干断层扫描进行定性和定量评估，以评估视网膜内液体变化和中心亚场厚度（CST）。结果：共分析41例患者62只眼，平均随访36.4±14.4周。接受3次ifi后，治疗间隔显著延长3.2周（P < 0.001）， CST显著降低43.8µm (P = 0.014)，视力保持稳定（ETDRS近似字母63.2 vs 64.4, P = 0.720）。17只眼睛（27.4%）被切换回先前的抗vegf药物，其中1例疑似ifi相关的葡萄膜炎。结论：对于一些需要改变抗vegf治疗的DME患者，Faricimab似乎是一个可行的选择。[眼科外科激光成像视网膜2025；56:XX-XX]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Early Outcomes of Faricimab Treatment for Diabetic Macular Edema in Patients Previously Treated With Anti-VEGF Therapy.

Background and objective: The aim of this study was to evaluate the short-term outcomes of switching to intravitreal faricimab injections (IFIs) from prior anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of diabetic macular edema (DME).

Patients and methods: A retrospective review was done of patients with DME previously treated with anti-VEGF and subsequently switched to IFIs. Optical coherence tomography scans were assessed qualitatively and quantitatively to evaluate intraretinal fluid changes and central subfield thickness (CST).

Results: A total of 62 eyes from 41 patients were analyzed with a mean follow-up time of 36.4 ± 14.4 weeks. After receiving three IFIs, treatment interval increased significantly by 3.2 weeks (P < 0.001), CST decreased significantly by 43.8 µm (P = 0.014), and visual acuity remained stable (63.2 vs 64.4 approximate ETDRS letters, P = 0.720). Seventeen eyes (27.4%) were switched back to their prior anti-VEGF agent, with one case of suspected IFI-related uveitis.

Conclusion: Faricimab appears to be a viable option for some DME patients who require a change in anti-VEGF therapy. [Ophthalmic Surg Lasers Imaging Retina 2025;56:XX-XX.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.